CDKN1A and breast cancer: In ER-negative, p53 mutant breast cancer cell lines, TSA treatment activates p21. Under these conditions, binding of p400 and H2A.Z to the p21 promoter was reduced, but the concomitant increase in H2A.Z acetylation was independent of TIP60.